Corporate News

Appointment of Joint Corporate Broker

04 December 2020

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product using hyperpolarised xenon-129 gas to enhance magnetic resonance imaging (MRI) in pulmonary medicine, is pleased to announce the appointment of Stifel Nicolaus Europe Limited as Joint Corporate Broker with immediate effect.



Polarean Imaging plc / 

Richard Hullihen, Chief Executive Officer 

Jonathan Allis, Chairman

Via Walbrook PR 




SP Angel Corporate Finance LLP Nomad and Broker

Tel: +44 (0)20 3470 0470  

David Hignell / Adam Cowl (Corporate Finance) 


Vadim Alexandre / Rob Rees (Corporate Broking)  




Stifel Nicolaus Europe Limited (Joint Corporate Broker)

Tel: +44 (0)20 7710 7600

Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking)


Nick Adams / Fred Walsh (Corporate Broking)



Walbrook PR 

Tel: +44 (0)20 7933 8780 or [email protected] 

Paul McManus / Anna Dunphy 

Mob: +44 (0)7980 541 893 / +44 (0)7876 741 001


About Polarean (

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

Investor Alert

Sign up for Email Alerts